ASR352, A potent anticancer agent: Synthesis, preliminary SAR, and biological activities against colorectal cancer bulk, 5-fluorouracil/oxaliplatin resistant and stem cells

Despite new agent development and short-term benefits in patients with colorectal cancer (CRC), metastatic CRC cure rates have not improved due to high rates of 5-fluorouracil (5-FU)/leucovorin/oxaliplatin (FOLFOX)-resistance and a clinical therapeutic plateau. At the same time, this treatment regim...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
izdano v:Eur J Med Chem
Main Authors: Narayan, Satya, Ramisetti, Srinivasa, Jaiswal, Aruna S., Law, Brian K., Singh-Pillay, Ashona, Singh, Parvesh, Amin, Shantu, Sharma, Arun K.
Format: Artigo
Jezik:Inglês
Izdano: Elsevier Masson SAS. 2019
Teme:
Research Paper
Online dostop:https://ncbi.nlm.nih.gov/pmc/articles/PMC7115410/
https://ncbi.nlm.nih.gov/pubmed/30384048
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ejmech.2018.10.052
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki